Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide DNA demethylation of HML58-3 (a derivative cell line of HCT116) after treatment of DAC, OR-2003, and OR-2100

ABSTRACT: Genome-wide DNA demethylation of HML58-3 (a derivative cell line of HCT116) after treatment of DAC, OR-2003, and OR-2100

PROVIDER: PRJNA554656 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Genome-wide DNA demethylation of HML58-3 (a derivative cell line of HCT116) after treatment of DAC, OR-2003, and OR-2100

Project description:A derivative cell line of HCT116, HML58-3, was established to detect DNA demethylating agents [Okochi-Takada E, Epigenetics. 2018;13:147-55.]. HML58-3 cells were treated with DNA demethylating agents (DAC, OR-2003, and OR-2100). Genome-wide DNA methylation was analyzed using the Infinium Human MethylationEPIC BeadChip.

2019-08-01 | GSE134293 | GEO

Genome-wide gene expression of HML58-3 (a derivative cell line of HCT116) after treatment of DAC (decitabine), OR-2003, and OR-2100

Project description:A derivative cell line of HCT116, HML58-3, was established to detect DNA demethylating agents [Okochi-Takada E, Epigenetics. 2018;13:147-55.]. HML58-3 cells were treated with DNA demethylating agents (decitabine, OR-2003, and OR-2100) or mock. A genome-wide gene expression analysis was performed using SurePrint G3 Human Gene Expression 8 x 60K v2 Microarray.

2019-08-01 | GSE134294 | GEO

Genome-wide gene expression of HML58-3 (a derivative cell line of HCT116) after treatment of DAC (decitabine), OR-2003, and OR-2100

Project description:Genome-wide gene expression of HML58-3 (a derivative cell line of HCT116) after treatment of DAC (decitabine), OR-2003, and OR-2100

| PRJNA554657 | ENA

dac

Project description:Drosophila melanogaster dac, dachshund, is differentially expressed in 15 experiment(s);

| FBgn0005677 | ExpressionAtlas

dac

Project description:Drosophila melanogaster dac, dachshund, is expressed in 4 baseline experiment(s);

| FBgn0005677 | ExpressionAtlas

Gene expression changes following demethylation by 5-aza-2'-deoxycytidine（decitabine, DAC）in mouse T cell lymphoma EL4 cells

2013-02-15 | GSE38473 | GEO

Paenibacillus sp. 2003 isolate:DPS 2003

Project description:Paenibacillus sp. 2003 isolate:DPS 2003 Genome sequencing and assembly

| PRJNA709402 | ENA

Gene expression changes following demethylation by 5-aza-2'-deoxycytidine（decitabine, DAC）in mouse T cell lymphoma EL4 cells

Project description:Our study had shown that DAC treatment enhanced immunogenecity of EL4 cells. To explore the mechanisms of DAC-induced tumor immunity, we carried out cDNA microarray analyses to compare the differential expression of genes between DAC and PBS treated EL4 cells. Two-condition experiment, PBS treated EL4 vs. Decitabine treated EL4 cells. Biological replicates: 3 PBS treated, 3 Decitabine treated, independently treatment and harvested. One replicate per array.

2013-02-15 | E-GEOD-38473 | biostudies-arrayexpress

scRNA-seq of DAC-treated and mock-treated HCT116.

Project description:Epigenetic reprogramming using demethylating drugs is a promising approach for cancer therapy, but its efficacy is highly dependent on the dosing regimen. Low-dose treatment for a prolonged period shows a high therapeutic efficacy, despite its small demethylating effect. Here, we aimed to reveal the mechanisms of how such low-dose treatment shows high efficacy by focusing on epigenetic reprograming at the single-cell level. Single-cell RNA-sequencing of HCT116 cells treated with decitabine (DAC) revealed that up-regulated genes were highly variable at the single-cell level. To analyze functional consequences at the single-cell level, DAC-treated HCT116 cells were cloned. While only partial reduction of methylation levels was observed in bulk cells, complete demethylation of specific cancer-related genes was observed, depending upon clones. For example, p16 was completely demethylated in the H3-32 clone out of 9 clones, and this clone showed slower proliferation than other clones without demethylation. In addition, in this clone, the fraction of cells with tetraploid became much larger, indicating that cellular senescence was induced. These results showed that epigenetic reprogramming of specific cancer-related pathways at the single-cell level is likely to underlie the high efficacy of low-dose DNA demethylating therapy.

2021-04-10 | GSE171429 | GEO

MRSA UKM 2003

Project description:MRSA UKM 2003 MRSA_P6

| PRJEB5444 | ENA